A report from China Securities Co., Ltd. highlights the high cost of Da Vinci surgeries, citing a Shanghai example where a single procedure cost around 30,000 yuan in 2024. This exceeds the latest national medical insurance fee standards, suggesting Da Vinci may face price adjustments as new regulations take effect. Since 2021, domestic surgical robots have received approvals, and their terminal prices are expected to drop significantly. By analyzing hospital profitability models, cost-effective domestic endoscopic robots and potential humanoid surgical robots could substantially lower surgical costs, boosting the adoption of robotic procedures.
Meanwhile, rapid advancements in embodied intelligence and humanoid robotics are driving high startup investment and frequent acquisitions by medical device leaders. Investors are advised to focus on companies capable of cost reduction and those fostering disruptive innovation. The report notes that frequent M&A activity among device leaders could create additional investment opportunities.
Key Insights from the Report:
The rapid development of robotics is driving surgical innovation. Specialized surgical robots are categorized by application and surgical type, including endoscopic, orthopedic, natural orifice (including ERCP), neurosurgical, and percutaneous puncture robots. Endoscopic robots represent the most commercially mature segment, followed by orthopedics, neurosurgery, and natural orifice applications. These robots offer both minimally invasive and precise benefits, with clear clinical advantages. For example, in prostate cancer surgery, where robotic assistance was first used, endoscopic robots have significantly reduced bleeding and complication rates, making robotic surgery the "gold standard."
Overseas Review: Consumables Elevate Valuation, Robots Dominate Minimally Invasive Surgery
A review of global surgical robot leader Intuitive Surgical (ISRG) reveals a three-stage business model: 1) Initial reliance on equipment—new models act as stock catalysts and are the primary early revenue source, though device launches are just the start; 2) The strong get stronger—new models expand surgical procedures, increasing per-machine surgery volumes and building a positive cycle; 3) Later reliance on consumables—by 2025, consumables account for 60% of Intuitive's revenue. The "device + consumables + service" model offers excellent valuations, with PS multiples rising from about 8x in the early stages to approximately 15x by 2025.
Market Potential: Tenfold Growth in a Decade, Nurturing a Hundred-Billion-Yuan Leader
According to Intuitive Surgical, Da Vinci robots have a global installed base of about 11,000 units, with roughly 500 in China, indicating extremely low market penetration. Considering device and service price reductions, the Chinese endoscopic robot market is expected to grow tenfold by 2035, reaching a market size of 33 billion yuan at factory prices. Assuming a domestic leader captures a 30% domestic market share, generates 50% of revenue from overseas, and achieves a 30% net profit margin by 2035, its revenue could approach 20 billion yuan, with profits near 6 billion yuan, sufficient to nurture a hundred-billion-yuan leader.
Industry Trends: Dual-Driven Upstream and Downstream, Disruptive Innovation Brewing
Da Vinci localization, new market entrants, and tech industry-driven upstream localization are expected to significantly lower surgical robot prices. According to fee standards set by the National Healthcare Security Administration and Hunan Province, robotic surgery charges could drop from 30,000-40,000 yuan to 15,000-25,000 yuan. The report suggests that sufficiently low device prices are essential for a positive cycle where "hospitals don't lose money, patients are willing to undergo surgery, and insurance can cover it," thus boosting robotic surgery penetration. Additionally, disruptive innovations like embodied intelligence and humanoid robots are entering animal testing stages, with potential for future clinical application.
Risk Factors: Risks include slower-than-expected product commercialization, high R&D difficulty and delayed approvals, intensified competition leading to price declines, medical accidents affecting reputation, and unexpected policy changes.
Investment Strategy: Focus on two main themes: robot cost reduction and continuous innovation. Three types of companies are favored: a) those with first-mover advantages and rapid innovation capabilities; b) platform companies with strong consumables capabilities; c) device leaders with ample capital, sustained innovation, and strong M&A capabilities. The report initiates coverage with an "Outperform" rating for the surgical robot industry.